Oppenheimer analyst Leah R. Cann has reiterated her Buy rating for Celgene Corporation (NASDAQ: CELG) after the firm’s pipeline drug Otezla has now become …
Juno Therapeutics Inc (NASDAQ:JUNO) and Celgene Corporation (NASDAQ:CELG) announced that the U.S.
Celgene Corporation (NASDAQ:CELG) announced that OTEZLA (apremilast), Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full marketing authorization by Japan’s Ministry …
Celgene Corporation (NASDAQ:CELG) announced that the results of its randomized phase II tnAcity trial of ABRAXANE for injectable suspension (paclitaxel protein-bound particles for injectable …
Celgene Corporation (NASDAQ:CELG) announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) …
In a research report released Monday, Cantor analyst Mara Goldstein reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price …
Lerink Swann analyst Geoff Porges weighed in today with a few insights on Celgene Corporation (NASDAQ:CELG), following investor meeting with Celgene’s CFO Peter Kellogg and Investor Relations …
Valeant: Sidelined on Uncertainty, but Short-Term Set-Up is a Positive Earlier this month, the rumor mill was clattering that Valeant Pharmaceuticals Intl Inc …
Celgene Corporation (NASDAQ:CELG) announced findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 …
In a research report released Friday, BTIG analyst Dane Leone reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price target …
